HILS Stock - Hillstream BioPharma, Inc.
Unlock GoAI Insights for HILS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-12,433,792 | $-9,455,220 | $-6,881,938 | $-3,208,017 | $-1,808,351 |
| Net Income | $-12,197,568 | $-9,319,094 | $-8,473,182 | $-3,037,920 | $-2,374,705 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-9.41 | $-7.14 | $-0.75 | $-0.30 | $-0.21 |
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Visit WebsiteEarnings History & Surprises
HILSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 13, 2023 | $-0.05 | $-0.11 | -110.5% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $0.16 | $0.16 | 0.0% | = MET |
Q2 2023 | May 22, 2023 | $0.11 | $0.23 | +109.1% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | — | $0.15 | — | — |
Q4 2022 | Nov 14, 2022 | — | $0.18 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-0.14 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.28 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.24 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.08 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.14 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.20 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.12 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.03 | — | — |
Latest News
Frequently Asked Questions about HILS
What is HILS's current stock price?
What is the analyst price target for HILS?
What sector is Hillstream BioPharma, Inc. in?
What is HILS's market cap?
Does HILS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HILS for comparison